The BOOST project seeks to combat HIV/AIDS and viral hepatitis in Europe through community-led harm reduction initiatives, aiming to enhance health services for people who use drugs and marginalised populations.
Thomson et al. examine coca, opium poppy and cannabis cultivation through the lens of agrarian political economy, drawing attention to key challenges for cultivators posed by synthetics and policy.
ICEERS report analyses the legal status of ayahuasca within Portuguese drug law and argues for increased legal clarity and consistent protection from criminalisation.
Over 30 European organisations acknowledge the failure of drug policies and demand a new approach prioritising health, rights, and community participation
Stevens et al. explain how decriminalising drug possession is an immediate first step towards reducing the harms of punitive drug policies and drug-related harm.
HRI highlight the continued violation of international human rights standards, reporting a record number of drug-related executions despite some positive policy developments.
Action for Safer Supply empower Canadian communities to address the toxic drug overdose crisis through key steps, including staying informed, demanding access, policy level advocacy and information sharing.
IDPC, HON, IDUCARE and SPINN outline barriers faced by women who use drugs in realising their health and right, showcases good practices of care and support, and proposes recommendations for reform.
Youth Rise underscore key challenges for young people who use opioids, including a lack of access to youth-tailored health and harm reduction, enduring stigma, and marginalisation.
Rusenga et al. explore the inequity experienced by small-scale cannabis farmers engaged in the nascent medical cannabis market and the factors that contribute to its continued illicit cultivation in Zimbabwe.
The HIV Legal Network provides recommendations on creating a safe and trusting environment through provision of staff training, promotion of knowledge exchange between staff and participants, and centering on people's lived experiences.
EMCDDA and Europol raise concerns on the threats of highly potent synthetic substances and the need to invest in harm reduction approaches, as one of the policy options to address the drug situation in Europe.
